Evaxion Biotech A/S (NASDAQ:EVAX) Sees Significant Growth in Short Interest

Evaxion Biotech A/S (NASDAQ:EVAX) saw a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 86,700 shares, a growth of 48.0% from the February 13th total of 58,600 shares. Based on an average daily volume of 2,250,000 shares, the short-interest ratio is currently 0.0 days. Approximately 8.2% of the shares of the stock are sold short.

Evaxion Biotech A/S Trading Down 0.5 %

Shares of EVAX stock traded down $0.01 on Friday, hitting $1.78. The company had a trading volume of 44,601 shares, compared to its average volume of 595,249. The firm has a market cap of $2.09 million, a P/E ratio of -1.23 and a beta of -0.25. The stock’s 50-day moving average is $2.86 and its two-hundred day moving average is $8.19. The company has a debt-to-equity ratio of 7.99, a quick ratio of 2.80 and a current ratio of 1.00. Evaxion Biotech A/S has a twelve month low of $1.70 and a twelve month high of $22.05.

Analyst Ratings Changes

EVAX has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $14.00 target price on shares of Evaxion Biotech A/S in a research note on Thursday, February 20th. Lake Street Capital decreased their price target on Evaxion Biotech A/S from $35.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, February 4th.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Invst LLC boosted its position in Evaxion Biotech A/S (NASDAQ:EVAX) by 16.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 50,400 shares of the company’s stock after buying an additional 7,200 shares during the quarter. Invst LLC owned approximately 4.31% of Evaxion Biotech A/S worth $43,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 11.04% of the company’s stock.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.